重组人促红细胞生成素联合不同剂量罗沙司他治疗维持性血液透析患者肾性贫血的安全性和有效性。

Safety and effectiveness of recombinant human erythropoietin coupled with different doses of Roxadustat for treatment of renal anemia in patients on maintenance hemodialysis.

作者信息

Wei Shanzhai, Sun Jie, Xu Kangchun, Li Yibei, Zhang Yilai

机构信息

Department of Nephrology, Shuyang Hospital of Traditional Chinese Medicine Shuyang 223600, Jiangsu, China.

出版信息

Am J Transl Res. 2023 Aug 15;15(8):5120-5128. eCollection 2023.

PMID:37692953

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10492066/

Abstract

OBJECTIVE

To investigate the safety and efficacy of recombinant human erythropoietin (rHuEPO) in combination with different doses of Roxadustat in treating renal anemia in patients on maintenance hemodialysis.

METHODS

Eighty patients with renal anemia on maintenance hemodialysis treated in Shuyang Hospital of Traditional Chinese Medicine from January 2020 to December 2021 were selected as study subjects, and they were divided into a study group (n=40, high-dose Roxadustat + rHuEPO therapy) and a control group (Con) (n=40, low-dose Roxadustat + rHuEPO therapy) in accordance with different therapies. The effects of anemia therapy, changes in anemia indicators (hemoglobin (Hb), hematocrit (Hct)), changes in iron metabolism indicators (transferrin saturation (TSAT), serum ferritin (SF)), changes in oxidative stress indicators Malondialdehyde (MDA), Superoxide Dismutase (SOD), and changes in microinflammatory indicators IL6, CRP were compared between the two groups. The occurrences of adverse effects during therapy were counted and compared between the two groups.

RESULTS

The therapy efficiency of the study group was 97.50% (39/40), which was higher than 85.00% (34/40) in the control group (=0.048). The contents of Hb, Hct, TSAT, and SF were higher in the study group than the Con after therapy (all ). The contents of MDA, IL6, and CRP were significantly lower in the study group than the Con after therapy (all <0.001). The occurrence of adverse effects was 10.00% in the study group, which was higher than 5.00% in the Con, but the difference was not significant (=0.396).

CONCLUSION

The combination of rHuEPO and high-dose Roxadustat (120 mg/time) has a better effect on improving anemia symptoms in maintenance hemodialysis patients than in those who take low dose Roxadustat (100 mg/time). It can significantly improve anemia and iron metabolism indicators and alleviate patients' inflammation and oxidative stress levels.

摘要

目的

探讨重组人促红细胞生成素（rHuEPO）联合不同剂量罗沙司他治疗维持性血液透析患者肾性贫血的安全性和有效性。

方法

选取2020年1月至2021年12月在沭阳中医院接受治疗的80例维持性血液透析肾性贫血患者作为研究对象，根据不同治疗方法分为研究组（n = 40，高剂量罗沙司他+rHuEPO治疗）和对照组（Con）（n = 40，低剂量罗沙司他+rHuEPO治疗）。比较两组贫血治疗效果、贫血指标（血红蛋白（Hb）、血细胞比容（Hct））变化、铁代谢指标（转铁蛋白饱和度（TSAT）、血清铁蛋白（SF））变化、氧化应激指标丙二醛（MDA）、超氧化物歧化酶（SOD）变化以及微炎症指标IL6、CRP变化。统计并比较两组治疗期间不良反应的发生情况。

结果

研究组治疗有效率为97.50%（39/40），高于对照组的85.00%（34/40）（=0.048）。治疗后研究组Hb、Hct、TSAT和SF含量均高于对照组（均）。治疗后研究组MDA、IL6和CRP含量均显著低于对照组（均<0.001）。研究组不良反应发生率为10.00%，高于对照组的5.00%，但差异无统计学意义（=0.396）。